Amycretin is an investigational single molecule that activates both GLP-1 and amylin receptors. Early randomised trials have studied oral and once-weekly subcutaneous formulations in overweight or obesity; neither formulation is approved.

Limited evidence. Review the research and limitations before relying on this record.

Amycretin combines GLP-1-receptor agonism with amylin-receptor agonism in one molecule. The intended complement is glucose-dependent insulin and glucagon control plus delayed gastric emptying and appetite reduction from GLP-1 signalling, together with amylin-mediated satiety and suppression of post-meal glucagon. A unimolecular agonist is not equivalent to mixing two independently adjustable medicines.

The published first-in-human programme reported approximately dose-proportional exposure across tested oral groups, while the subcutaneous phase 1b/2a programme supported weekly administration. The available abstracts do not establish one formulation-independent half-life, and early dose-escalation pharmacokinetics should not be converted into a public-use protocol.

The evidence is early and sponsor-funded. A 144-participant first-in-human programme assessed oral amycretin, and a separate 125-participant single-centre phase 1b/2a trial assessed subcutaneous amycretin for up to 36 weeks. Both found body-weight reductions that supported further study, but the trials were designed primarily around safety, tolerability and pharmacokinetics; they were not confirmatory phase 3 efficacy trials.

Gastrointestinal events were the dominant treatment-emergent adverse effects and increased with exposure in the oral programme; most reported events were mild or moderate. The subcutaneous study had substantial withdrawal, including many discontinuations for reasons not attributed to adverse events. Larger and more diverse trials are required to define uncommon harms, long-term tolerability and cardiovascular outcomes. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.

This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.